natgillin/translations-raw huggingface dataset:
• Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 
• odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR - platelet derived growth factor receptor);
Vincristine 2 mg i.v., days 4, 11; Doxorubicine 50 mg/m2 i.v. 
vinkristin 2 mg i.v., 4., 11. dan; doksorubicin 50 mg/m2 i.v.
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy. 
Opravili so tri velike mednarodne odprte nekontrolirane študije druge faze pri bolnikih s KML, s prisotnim kromosomom Philadelphia (Ph+), v napredovali, blastni ali pospešeni fazi bolezni, z drugimi Ph+ levkemijami ali s KML v kronični fazi, a po predhodnem neuspešnem zdravljenju z interferonom alfa (IFN).
Ara-C 60 mg/m2 i.v., days 22-25, 29-32 
Ara-C 60 mg/m2 i.v., 22.-25., 29.-32. dan
Chronic phase CML is defined when all of the following criteria are met: blasts < 15% in blood and bone marrow, peripheral blood basophils < 20%, platelets > 100 x 109/l. 
Kronična faza KML je opredeljena z naslednjimi kriteriji: blasti < 15 % v krvi in kostnem mozgu, bazofilci v periferni krvi < 20 %, trombociti > 100 x 109/l.
If laboratory or clinical findings associated with TMA occur in a patient receiving Imatinib Teva , treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and antiADAMTS13-antibody determination, should be completed. 
Če se pri bolniku, ki prejema zdravilo Imatinib Teva, pojavijo laboratorijski ali klinični znaki trombotične mikroangiopatije, je treba zdravljenje prekiniti in izvesti temeljito oceno pojava trombotične mikroangiopatije, vključno z aktivnostjo ADAMTS13 in določanjem protiteles proti ADAMTS13.
Pregnancy, breast-feeding and fertility - If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitor, ATC code: L01XE01 
Farmakoterapevtska skupina: Druga zdravila z delovanjem na novotvorbe , zaviralec protein-kinaze, oznaka ATC: L01XE01
Doses of 400 mg or 600 mg should be administered once daily, whereas a daily dose of 800 mg should be administered as 400 mg twice a day, in the morning and in the evening. 
Odmerke po 400 mg ali 600 mg je treba jemati enkrat na dan, medtem ko je treba odmerek 800 mg na dan vzeti kot 400 mg dvakrat na dan, zjutraj in zvečer.
- The other ingredients are calcium hydrogen phosphate, crospovidone and magnesium stearate. 
- Druge sestavine zdravila so kalcijev hidrogenfosfat, krospovidon in magnezijev stearat.
The percentage of some adverse reactions was higher in the 40 patients in whom the dose was increased to 800 mg daily compared to the population of patients before dose increase (n=551). 
Odstotni delež nekaterih neželenih reakcij je bil večji pri tistih 40 bolnikih, pri katerih je bil odmerek zvečan na 800 mg na dan, kot pri populaciji bolnikov pred zvečanjem odmerka
Pancytopenia, febrile neutropenia 
pancitopenija, febrilna nevtropenija občasni:
Myeloid blast crisis 
Mieloidna blastna kriza
(≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), 
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Continuous daily exposure to imatinib early in the course of treatment in combination with chemotherapy in cohort 5-patients (n=50) improved the 4-year event-free survival (EFS) compared to historical controls (n=120), who received standard chemotherapy without imatinib (69.6% vs. 31.6%, respectively). 
Pri bolnikih v 5. kohorti (n=50) je neprekinjena vsakodnevna izpostavljenost imatinibu zgodaj v poteku zdravljenja v kombinaciji s kemoterapijo povečala delež bolnikov s 4-letnim preživetjem brez dogodkov (EFS - event-free survival) v primerjavi z zgodovinskimi kontrolami (n=120), kjer so bolniki prejeli standardno kemoterapijo brez imatiniba (69,6 % v primerjavi z 31,6 %).
If you take more Imatinib Teva than you should If you have accidentally taken too many tablets, talk to your doctor straight away. 
Če ste vzeli večji odmerek zdravila Imatinib Teva kot bi smeli Če ste pomotoma vzeli preveč tablet, se nemudoma posvetujte z zdravnikom.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Tega zdravila ne smete uporabljati po datumu uporabnosti, ki je naveden na stični ovojnini in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non-responses were censored at the date of last examination. 
Stopnje popolnega hematološkega odziva, pomembnega citogenetičnega odziva in popolnega citogenetičnega odziva pri zdravljenju z zdravilom prvega izbora so ocenili po Kaplan-Meierjevi metodi, za katero so izide ne-odzivnosti določili na datum zadnjega pregleda.
If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 400 mg. 
Če citopenija ni povezana z levkemijo, zmanjšajte odmerek imatiniba na 400 mg.
Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.). 
Imatinib lahko zveča plazemske koncentracije drugih zdravil, ki jih presnavlja CYP3A4 (na primer triazolo-benzodiazepinov, dihidropiridinskih zaviralcev kalcijevih kanalčkov, nekaterih zaviralcev reduktaze HMG-CoA, tj. statinov, itd.).
The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia (i.e. clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML. 
Primarna učinkovitostna spremenljivka je bila stopnja hematološkega odziva, opisanega kot popolni hematološki odziv, kot odsotnost vseh znakov levkemije (tj., izginotje blastov iz kostnega mozga in krvi, a brez popolnega okrevanja periferne krvi kot pri popolnem odzivu), ali kot vrnitev v kronično fazo KML.
• Feeling sick (nausea), with loss of appetite, dark-coloured urine, yellow skin or eyes (signs of liver problems). 
• občutek slabosti s siljenjem na bruhanje (navzea) z izgubo apetita, temno obarvan urin, rumena koža ali oči (znaki težav z jetri),
Total bilirubin: = 1.5 ULN AST: >ULN (can be normal or < ULN if total bilirubin is > ULN) 
AST: > IULN (lahko je normalna ali < IULN, če je celotni bilirubin >
(1 h), days 1-3; Vincristine 1.3 mg/m2 i.v., days 1, 8, 15, 21; 
(1 ura), 1.-3. dan; vinkristin 1,3 mg/m2 i.v., 1., 8., 15., 21. dan;
In this study 65% of the patients achieved a major cytogenetic response that was complete in 53% (confirmed 43%) of patients (Table 3). 
V tej študiji je 65 % bolnikov doseglo pomemben citogenetični odziv, ki je bil popoln pri 53 %
Depending on your condition the usual starting dose is either 400 mg or 600 mg: 
Če se zdravite zaradi KML: Glede na fazo bolezni je običajni začetni odmerek bodisi 400 mg ali 600 mg:
Progression was defined as any of the following events: progression to accelerated phase or blast crisis, death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite appropriate therapeutic management. 
Napredovanje je bilo definirano kot katerikoli od sledečih dogodkov: napredovanje v pospešeno fazo ali blastno krizo, smrt, izguba popolnega hematološkega odziva ali pomembnega citogenetičnega odziva, oziroma pri bolnikih, ki niso dosegli popolnega hematološkega odziva, rast WBC kljub ustreznemu zdravljenju.
(1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/m2 oral, days 26-46 
(1 ura), 28.-31., 35.-38., 42.-45. dan; 6-MP 60 mg/m2 peroralno, 26.-46. dan
DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/m2 i.v. 
DEX 40 mg/dan 1.-4. in 11.-14. dan, izmenjaje z MTX 1 g/m2 i.v.
This Ki value is far higher than the expected plasma levels of imatinib in patients; consequently no interaction is expected upon co-administration of either 5-fluorouracil or paclitaxel and imatinib. 
Ta vrednost Ki je mnogo večja kot pričakovane plazemske koncentracije imatiniba pri bolnikih, zato po sočasnem dajanju bodisi 5-fluorouracila ali paklitaksela in imatiniba ni pričakovati medsebojnega delovanja.
If elevations in bilirubin > 3 x institutional upper limit of normal (IULN) or in liver transaminases > 5 x IULN occur, imatinib should be withheld until bilirubin levels have returned to < 1.5 x IULN and transaminase levels to < 2.5 x IULN. 
Če pride do zvišanja bilirubina na > 3-kratno zgornjo mejo normalnih vrednosti, specifično za ustanovo, (IULN-institutional upper limit of normal) ali zvišanja jetrnih aminotransferaz na > 5-kratno IULN, je treba zdravljenje z imatinibom prekiniti, dokler se koncentracija bilirubina ne vrne na < 1,5 kratno IULN oziroma koncentracija aminotransferaz na < 2,5-kratno IULN.
The primary efficacy endpoint of the study is progression-free survival. 
V študiji je bil primarni cilj opazovanja glede učinkovitosti preživetje brez napredovanja bolezni.
Dose adjustments do not seem to be necessary when imatinib is co-administrated with CYP2D6 substrates, however caution is advised for CYP2D6 substrates with a narrow therapeutic window such as metoprolol. 
prilagajanje odmerkov ni potrebno, vendar pa je potrebna previdnost pri substratih CYP2D6 z ozkim terapevtskim oknom, kot je metoprolol.
BM = bone marrow, PB = peripheral blood 2 Cytogenetic response criteria: 
BM = kostni mozeg, PB = periferna kri
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events. 
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF - platelet derived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
They may increase or decrease the effect of Imatinib Teva, either leading to increased side effects or making Imatinib Teva less effective. 
Lahko povečajo ali zmanjšajo učinek zdravila Imatinib Teva in zato bodisi povečajo verjetnost za nastanek neželenih učinkov, bodisi zmanjšajo učinkovitost zdravila Imatinib Teva.
- Patients who are concerned about their fertility while taking Imatinib Teva are advised to consult with their doctor. 
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z imatinibom, naj se posvetujejo s svojim zdravnikom.
At a dose of 60 mg/kg, female rats had significant post-implantation foetal loss and a reduced number of live foetuses. 
Pri odmerku 60 mg/kg je prišlo pri samicah do znatne izgube plodov po vgnezditvi in do zmanjšanja števila živorojenih plodov.
What Imatinib Teva is and what it is used for 
Kaj je zdravilo Imatinib Teva in za kaj ga uporabljamo
Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white cells (named lymphoblasts) start growing out of control. 
Akutna limfoblastna levkemija je oblika levkemije, pri kateri se začnejo nenadzorovano razraščati določene nenormalne bele krvničke (imenovane limfoblasti).
Imatinib is mainly metabolised through the liver. 
Imatinib se presnavlja predvsem v jetrih.
In adults the dose should be reduced from 400 mg to 300 mg or from 600 mg to 400 mg or from 800 mg to 600 mg, and in children from 340 to 260 mg/m2/day. 
Pri odraslih je treba zmanjšati odmerek s 400 mg na 300 mg ali s 600 mg na 400 mg ali z 800 mg na 600 mg, pri otrocih pa s 340 mg/m2/dan na 260 mg/m2/dan.
Total bilirubin: > 1.5-3.0 ULN AST: any 
zmerna celotni bilirubin: > 1,5-3,0 IULN AST: kakršnakoli težka celotni bilirubin: > 3-10 IULN AST: kakršnakoli
Hyperkalaemia, hypomagnesaemia 
hiperkaliemija, hipomagneziemija
There is very limited experience in children with MDS/MPD, DFSP and HES/CEL. 
Izkušnje pri otrocih z MDS/MPD, DFSP in HES/CEL so zelo omejene.
Chronic phase CML, MDS/MPD (starting dose 400 mg) HES/CEL (at dose 400 mg) 
kronična faza KML, MDS/MPD (začetni odmerek 400 mg)
(24 h), day 1, 
(24 ur), 1. dan,
Study AJP01 Induction therapy 
Študija AJP01
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at ≥30 mg/kg/day. 
V 2-letni študiji karcinogenosti pri podganah je odmerjanje imanitiba 15 mg/kg/dan, 30 mg/kg/dan in 60 mg/kg/dan povzročilo statistično značilno skrajšanje življenjske dobe samcev pri 60 mg/kg/dan in samic pri ≥ 30 mg/kg/dan.
The diameter of the film-coated tablet is approximately 9 mm. 
Premer filmsko obložene tablete je približno 9 mm.
The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 1.2 times the daily exposure in children (based on AUC) at 340 mg/m2/day. 
Adenome/karcinome ledvic, papilome sečnega mehurja in sečnice, adenokarcinome tankega črevesa, adenome obščitničnih žlez, benigne in maligne medularne tumorje nadlevičnih žlez in papilome/karcinome ne-žleznega dela želodca so opazili pri odmerku 60 mg/kg/dan, kar predstavlja približno 1,7 do 1-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan in 1,2-kratnik dnevne izpostavljenosti otrok (na podlagi AUC) pri 340
In this study, dose escalations were allowed from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily. 
V tej študiji so bila dovoljena zvečanja odmerka s 400 mg na dan na 600 mg na dan, nato s 600 mg na dan na 800 mg na dan.
The no observed effect level (NOEL) for both the maternal animals and the F1 generation was 15 mg/kg/day (one quarter of the maximum human dose of 800 mg). 
tako na samice-matere kot na generacijo F1 je bil 15 mg/kg/dan (ena četrtina največjega odmerka za človeka, ki je 800 mg).
The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia or return to chronic phase CML using the same criteria as for the study in accelerated phase. 
Primarna učinkovitostna spremenljivka je bila stopnja hematološkega odziva, opisanega bodisi kot popolni hematološki odziv, kot odsotnost dokazov levkemije ali kot vrnitev v kronično fazo KML, pri čemer so uporabljali enaka merila kot pri študiji v pospešeni fazi.
One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. 
V enem odprtem multicentričnem kliničnem preskušanju faze II (študija B2225) so preskušali imatinib pri različnih populacijah bolnikov z življensko ogrožujočimi boleznimi v povezavi z Abl, Kit ali PDGFR protein tirozin kinazami.
• Combination of a widespread severe rash, feeling sick, fever, high level of certain white blood cells or yellow skin or eyes (signs of jaundice) with breathlessness, chest pain/discomfort, severely decreased urine output and feeling thirsty etc. (signs of a treatment-related allergic reaction). 
• kombinacija hudo razširjenega hudega izpuščaja, slabosti s siljenjem na bruhanje, povišane telesne temperature, visoke vrednosti nekaterih vrst belih krvnih celic ali rumene obarvanosti kože ali oči (znaka zlatenice) z zasoplostjo, bolečino/neugodjem v prsnem košu, izrazito zmanjšanim izločanjem urina in žejo itd. (znaki alergijske reakcije na zdravljenje).
Active substances that may increase imatinib plasma concentrations 
Učinkovine, ki lahko zvišajo plazemske koncentracije imatiniba:
• Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. 
• odraslih in pediatričnih bolnikov z na novo diagnosticirano akutno limfoblastno levkemijo, s prisotnim kromosomom Philadelphia (Ph+ ALL) skupaj s kemoterapijo;
30 film-coated tablets 30x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets 
30 filmsko obloženih tablet 30x1 filmsko obloženih tablet 90 filmsko obloženih tablet 90x1 filmsko obloženih tablet
The doctor will tell you how many tablets of Imatinib Teva to give to your child. 
Zdravnik vam bo povedal, koliko tablet zdravila Imatinib Teva dajte svojemu otroku.
The total daily dose in children and adolescents must not exceed 800 mg with CML and 600 mg with Ph+ALL. 
Celotni dnevni odmerek pri otrocih ne sme preseči 800 mg pri zdravljenju KML in 600 mg pri zdravljenju Ph pozitivne ALL.
The length of the film-coated tablet is approximately 20 mm and the width is approximately 10 mm. 
Dolžina filmsko obložene tablete je približno 20 mm in širina približno 10 mm.
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months. 
14 mesecev, bolniki pa so bili vsi v pozni kronični fazi s povprečnim časom 32 mesecev od postavitve diagnoze.
At the time of the original analysis, three of the four patients with detected PDGFR gene rearrangements developed haematological response (2 CHR and 1 PHR). 
času prvotne analize so trije od štirih bolnikov z dokazano preureditvijo gena za PDGFR dosegli hematološki odziv (2 sta dosegla popolni in 1 delni hematološki odziv).
5 patients responded, 3 completely and 2 partially. 
bolnikih, pri enem do popolnega in pri 8 do delnega.
Imatinib Teva is also a treatment for children and adolescents with CML. 
Zdravilo Imatinib Teva je namenjeno tudi zdravljenju otrok s KML.
Relapsed/refractory Ph+ ALL 
Relaps/neodzivna Ph+ ALL
Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59), respectively. 
Hematološki odzivi so ostali enaki mediano 49 mesecev (od 19 do 60), citogenetični odzivi pa 47 mesecev (od 16
(24 h), days 1, 15; 6-MP 25 mg/m2 oral, days 1-20 
(24 ur), 1., 15. dan; 6-MP 25 mg/m2 peroralno, 1.-20. dan
- If you are being treated for HES/CEL: 
Če se zdravite zaradi HES/CEL:
The capsules are approximately 19 mm long and 7 mm wide. 
Kapsule so približno 19 mm dolge in 7 mm široke.
Teva Pharma B.V. Swensweg 5, 2031 GA Haarlem The Netherlands 
Teva B.V., Swensweg 5, 2031 GA Haarlem, Nizozemska
(3 h, q 12 h), 
(3 ure, na 12 ur),
Herpes zoster, herpes simplex, nasopharyngitis, pneumonia1, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis 
herpes zoster, herpes simpleks, nazofaringitis, pljučnica1, sinuzitis, flegmona, okužba zgornjih dihal, gripa, okužba sečil, gastroenteritis, sepsa redki:
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice: 
Če ne morete pogoltniti tablet, jih lahko raztopite v kozarcu navadne vode ali jabolčnega soka:
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Pilogo I : Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the imatinib arm compared to the IFN arm (92.5% versus 85.1%, p<0.001). 
Ocenjeni odstotek bolnikov, ki niso napredovali v pospešeno fazo ali blastno krizo pri 84 mesecih, je bil bistveno večji na kraku z imatinibom v primerjavi s krakom z IFN (92,5 % proti 85,1 %, p < 0,001).
(1 h) day 1; 
(1 ura) 1. dan;
(2 h, q 12 h), days 2-3 (total of 8 
(2 uri, na 12 ur), 2.-3. dan (skupno 8 kur)
1 Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST. 
O pljučnici so najpogosteje poročali pri bolnikih s transformacijo KML in pri bolnikih z
In study I2301, a total of 93 paediatric, adolescent and young adult patients (from 1 to 22 years old) with Ph+ ALL were enrolled in an open-label, multicentre, sequential cohort, non-randomized phase III trial, and were treated with imatinib (340 mg/m2/day) in combination with intensive chemotherapy after induction therapy. 
V odprto, nerandomizirano, multicentrično preizkušanje faze III z oznako I2301 in z zaporednimi kohortami so vključili skupno 93 otrok, mladostnikov in mladih odraslih (starih od 1 do 22 let) s Ph+ ALL in jih zdravili z imatinibom (340 mg/m2/dan) v kombinaciji z intenzivno kemoterapijo po indukcijskem zdravljenju.
• Signs of infection such as fever, severe chills, sore throat or mouth ulcers. 
• znaki okužbe, na primer povišana telesna temperatura, huda mrzlica, vnetje žrela ali razjede po ustih.
Posology for CML in paediatric patients Dosing for children should be on the basis of body surface area (mg/m2). 
Odmerjanje pri KML pri otrocih Odmerjanje za otroke mora temeljiti na telesni površini (mg/m2).
3 On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML. 
3 Dogodke v zvezi s srcem, vključno s kongestivno odpovedjo srca, so na podlagi enote bolnikleto pogosteje opažali pri bolnikih s transformacijo KML kot pri bolnikih s kroničnim potekom KML.
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy. 
• odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji;
(q 12 h), days 2-3, for 4 cycles 
(na 12 ur), 2.-3. dan, v 4 ciklusih
When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30% (9% complete) and a major cytogenetic response rate of 23%. 
Zdravljenje z imatinibom kot edinim zdravilom pri bolnikih z relapsom/neodzivno Ph+ ALL je povzročilo pri 53 od 411 za oceno odziva primernih bolnikov stopnjo hematološkega odziva 30 % (v 9 % popolni hematološki odziv) in stopnjo pomembnega citogenetičnega odziva 23 %.
• Muscle weakness and spasms with an abnormal heart rhythm (signs of changes in the amount of potassium in your blood). 
• oslabelost mišic in mišični spazmi z nepravilnim ritmom bitja srca (znaki spremenjenih vrednosti kalija v krvi), • modrice,
9/l) and thrombocytopenias frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 10 (platelet count < 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia). 
Nevtropenija 3. ali 4. stopnje (ANC < 1,0 x 109/l) in trombocitopenija (koncentracija trombocitov < 50 x 109/l) sta bili štirikrat do šestkrat pogostejši v blastni krizi in pospešeni fazi (nevtropenija 59-64 % in trombocitopenija 44-63 %) kot pri na novo diagnosticiranih bolnikih v kronični fazi KML (nevtropenija 16,7 % in trombocitopenija 8,9 %).
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people): 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) ali redki (pojavijo se lahko pri največ 1 od
Imatinib Teva is indicated for 
Zdravilo Imatinib Teva je indicirano za: